Aerotek’s clients gain increased access to qualified candidates for their positions with the company's acquisition of Kforce’ scientific division.
Aerotek Scientific® LLC, a subsidiary of Aerotek, Inc., is excited to announce the acquisition of the scientific division of Kforce. Aerotek (www.aerotek.com) is a leading provider of technical, professional and industrial recruiting and staffing. Financial details of the acquisition have not been disclosed by company officials.
Aerotek acquired the employees, clients, contractors, and relevant data of the scientific division of Kforce. Staff previously employed by the scientific division of Kforce will continue to service their clients and contractors while working for Aerotek Scientific.
Aerotek Scientific places candidates of all levels at a variety of companies in many industries including: pharmaceuticals, biotechnology, healthcare, food & beverage, clinical research, chemical and plastics. The scientific division of Kforce’s similar focus on these markets complements Aerotek’s existing structure and will expand the company throughout the scientific industry. Kforce will retain the recruitment services that apply to the clinical trials industry.
“The acquisition of the scientific division of Kforce strengthens the presence of Aerotek Scientific within niche scientific industries nationwide,” said Thomas M. Thornton, president and chief executive officer of Aerotek. In addition to the internal growth from which our company will benefit, former Kforce Scientific and existing Aerotek clients now have access to a larger pool of qualified candidates for their positions, and contract employees have significantly more jobs available to them through our services.”
As technologies evolve and new career specialties emerge, the market for scientific professionals has continued to increase. The demand for qualified, experienced talent in scientific industries has become progressively competitive. The acquisition of the scientific division of Kforce bolsters Aerotek’s collective expertise and reinforces the company’s position as a leader in this marketplace.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.